New Delhi, June 19 -- India's pharmaceutical industry is poised to gain significantly from an upcoming wave of patent expiries, with CareEdge Ratings estimating a USD 3-5 billion opportunity for Indian drugmakers over the next five years.

According to a report released by CareEdge Ratings, patents on drugs generating nearly USD 142 billion in annual sales in calendar year 2025 are expected to expire between 2026 and 2030, paving the way for generic and biosimilar manufacturers to enter the market.

The report noted that after accounting for steep price erosion following the loss of exclusivity, the global opportunity could exceed USD 30-40 billion over five years, of which Indian companies are expected to capture around USD 3-5 billion....